Drugs decrease diabetic patients with renal function


Lambers Heerspink and his co-investigators included 4400 patients with type 2 diabetes and chronic kidney disease in 34 countries. Half received the drug canagliflozin, the other half received a placebo. Patients were followed for more than 2.5 years.

At the end of this period, the probability of dying from kidney failure or having developed the final phase of the disease was 30 percent lower in the study group than in the control group.

The risk of death from cardiovascular disease, hospitalizations for heart failure and the risk of heart attacks or strokes were also about one third lower in the treated group than in the placebo group.


"For nearly two decades there have been no new treatments to protect kidney function in patients with type 2 diabetes. This research result is a breakthrough medical because people with diabetes and kidney disease are at an extremely high risk of kidney failure, heart attack , stroke and death.We now have a very effective way of reducing this, "Lambers Heerspink said in a UMCG press release.

The Diabetes Association responds cautiously to the new results of the research. However, the organization points out that the new treatment applies to a limited group of patients with kidney failure caused by type 2 diabetes.

The Diabetes Association further notes that the study on the use of canagliflozin by Lambers Heerspink and his colleagues was sponsored by the manufacturer of the drug.


Lambers Heerspink and colleagues in The Lancet Diabetes & Endocrinology published a second study on the treatment of diabetes 2. If patients receive the drug dapagliflozin in combination with a third drug (saxagliptin), this combination will have a stronger effect than other medications. sugar and blood protein content in the urine.

This plays an important role in the development of renal failure. The combination of both drugs slows the decline of kidney function. This study is also financially supported by the manufacturer of the investigational drug.

The new insights that emerge from the studies of the teacher of Groningen and his fellow researchers can, according to themselves, be put into practice immediately. The drugs investigated are drugs approved for the treatment of type 2 diabetes.

But, according to the Diabetes Association, there is still a need to consult ahead of time. In addition, she believes further research is needed.


Source link